Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?

Arthritis Research & Therapy, Jan 2005

Pleiotropic effects are now described for the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (or statins) that might have utility in the context of chronic inflammatory autoimmune disease. Here we discuss the pharmacology and established uses of statins and in this context describe potential anti-inflammatory and immune-modulatory effects. An extensive in vitro data set defines roles for statins in modifying endothelial function, particularly with respect to adhesion molecule expression and apoptosis. Broader effects on leukocyte function have now emerged including altered adhesion molecule expression, cytokine and chemokine release and modulation of development of adaptive immune responses via altered MHC class II upregulation. In vivo data in several inflammatory models, including collagen-induced inflammatory arthritis and experimental autoimmune encephalomyelitis, suggest that such effects might have immune-modulatory potential. Finally, a recent clinical trial has demonstrated immunomodulatory effects for statins in patients with rheumatoid arthritis. Together with their known vasculoprotective effects, this growing body of evidence provides compelling support for longer-term trials of statin therapy in human disease such as rheumatoid arthritis.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://arthritis-research.com/content/pdf/ar1496.pdf

Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?

Arthritis Research & Therapy Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? David W McCarey1, Naveed Sattar2 and Iain B McInnes1 Corresponding author: Iain B McInnes 0 Department of Vascular Biochemistry, Glasgow Royal Infirmary , Glasgow , UK 1 Centre for Rheumatic Diseases, Glasgow Royal Infirmary , Glasgow , UK Pleiotropic effects are now described for the 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitors (or statins) that might have utility in the context of chronic inflammatory autoimmune disease. Here we discuss the pharmacology and established uses of statins and in this context describe potential anti-inflammatory and immune-modulatory effects. An extensive in vitro data set defines roles for statins in modifying endothelial function, particularly with respect to adhesion molecule expression and apoptosis. Broader effects on leukocyte function have now emerged including altered adhesion molecule expression, cytokine and chemokine release and modulation of development of adaptive immune responses via altered MHC class II upregulation. In vivo data in several inflammatory models, including collagen-induced inflammatory arthritis and experimental autoimmune encephalomyelitis, suggest that such effects might have immune-modulatory potential. Finally, a recent clinical trial has demonstrated immunomodulatory effects for statins in patients with rheumatoid arthritis. Together with their known vasculoprotective effects, this growing body of evidence provides compelling support for longer-term trials of statin therapy in human disease such as rheumatoid arthritis. - Introduction Statins were developed and tested clinically on the basis of their capacity to suppress cholesterol biosynthesis and thereby modify an important vascular risk factor. Numerous clinical studies have demonstrated efficacy in this respect, both in secondary and primary prevention strategies. A significant recent advance in understanding vascular risk has identified the utility of C-reactive protein (CRP) and, by implication, inflammation as an important pathogenetic factor in atherogenic pathogenesis. In parallel, there has been increasing recognition that the vasculoprotective effects of statins might reside not only in lipid modification but also in direct effects on inflammation manifested presumably through direct effects on the vascular lesion, or via secondary modification of the hepatic acute-phase response and constituent moieties, particularly CRP. CRP measured in this context is typically of low concentration measured via high-sensitivity assays. A logical question arising from such studies concerns the capacity of statins, or statin-sensitive pathways, to operate in the context of high-grade inflammation such as that characteristically seen in autoimmune diseases such as rheumatoid arthritis (RA). Pharmacology of the HMG-CoA reductase inhibitors The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase catalyses the conversion of HMG-CoA to mevalonic acid and is a rate-limiting step in the cholesterol biosynthetic pathway. Statins are selective, competitive inhibitors of this enzyme and are effective lipid-lowering drugs in humans. They decrease hepatic cholesterol synthesis, promoting the upregulation of low-density lipoprotein (LDL)-cholesterol receptors and increasing the removal of LDL-cholesterol from the plasma [1]. Numerous derivatives generated in this pathway, including squalenederived moieties, farnesyl pyrophosphate and geranylgeranyl pyrophosphate (GGP), in turn might interact with additional cell signalling pathways, some of which might have immune-modulatory potential. Five statins are currently available within the UK: pravastatin, simvastatin, fluvastatin, atorvastatin and rosuvastatin; in addition, lovastatin is available in other countries. Cerivastatin has been withdrawn from sale because of concerns over adverse events [2] (Fig. 1). Lovastatin is a fungal metabolite, of which pravastatin and simvastatin are semi-synthetic derivatives, whereas fluvastatin, atorvastatin and rosuvastatin are entirely synthetic [1]. Lovastatin and simvastatin are of the lactone CI = confidence interval; CIITA = class II transactivator; CRP = C-reactive protein; GGP = geranylgeranyl pyrophosphate; HMG-CoA = 3-hydroxy3-methylglutaryl-coenzyme A; HUVEC = human umbilical-vein endothelial cells; ICAM = intercellular cell-adhesion molecule; IFN = interferon; IL = interleukin; LDL = low-density lipoprotein; LFA = leukocyte function antigen; MCP = monocyte chemotactic protein; NFB = nuclear factor B; PPAR = peroxisome-proliferator-activated receptor; RA = rheumatoid arthritis; Th = T helper; TNF = tumour necrosis factor; VCAM = vascular celladhesion molecule. Molecular structures of some of the HMG-CoA reductase inhibitors. (From [3]; reproduced by permission of The American Society for Pharmacology and Experimental Therapeutics.) pro-drug form, whereas ato (...truncated)


This is a preview of a remote PDF: http://arthritis-research.com/content/pdf/ar1496.pdf

David W McCarey, Naveed Sattar, Iain B McInnes. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?, Arthritis Research & Therapy, 2005, pp. 55-61, 7, DOI: 10.1186/ar1496